TICKERNERD
Menu
NAGENAGEHealthcare · Biotechnology

NAGE Stock Forecast: Niagen Bioscience, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.21
+1.90% on the day

The 6 Wall Street analysts covering Niagen Bioscience, Inc. hold a median 12-month price target of $11 — +227.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$254.0M
Ticker Nerd rank
54 / 100
Median analyst target
$11
Analysts covering
6
Total return, dividends reinvested
1W
+6.3%
1M
−8.0%
YTD
−49.5%
1Y
−67.1%
From 52W high
−68.7%
From 52W low
+8.4%
$3
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Niagen Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
96
Issuance
81
Volatility
76
Size
65
Growth
32
Revisions
30
Accruals
17
Momentum
10

Quality (98): The business earns solid, repeatable profits on what it owns.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NAGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26NAGEHigh $22Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $9Median $11High $22

The green dot is the last close — the median target sits +227.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026HC Wainwright & Co.MaintainsBuy$12 → $11
5 May 2026Canaccord GenuityMaintainsBuy$13 → $10
31 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Nov 2025Canaccord GenuityMaintainsBuy—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 June 2025Canaccord GenuityMaintainsBuy—
6 June 2025Roth CapitalMaintainsBuy—
27 May 2025Canaccord GenuityInitiatesBuy—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Mar 2025HC Wainwright & Co.MaintainsBuy—
5 Mar 2025Ladenburg ThalmannMaintainsBuy—
6 Nov 2024Roth MKMMaintainsBuy—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NAGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−62.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Niagen Bioscience, Inc. (NAGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.9×

Cheaper than 44% of US stocks

Price / sales
2.0×

Cheaper than 53% of US stocks

Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
19.8×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
−4.3%

Higher than 21% of US stocks

Earnings growth (YoY)
−73.3%

Higher than 6% of US stocks

Gross margin
64.8%

Higher than 78% of US stocks

Operating margin
2.4%

Higher than 49% of US stocks

Net margin
12.4%

Higher than 74% of US stocks

Returns & dividend
Return on equity
21.8%

Higher than 83% of US stocks

Return on assets
5.4%

Higher than 78% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NAGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAGENiagen Bioscience, Inc.$254.0M
54
SLGLSol-Gel Technologies Ltd.$254.1M
45
PYXSPyxis Oncology, Inc.$256.9M
80
ALECAlector, Inc.$257.6M
42
MGNXMacroGenics, Inc.$260.6M
67
CGENCompugen Ltd.$247.3M
82
GLSIGreenwich LifeSciences, Inc.$244.7M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Niagen Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAGE news & analysis

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

Business Wire · 20 Aug 2026positive

Niagen Bioscience announced that Tru Niagen, its healthy-aging NAD-boosting supplement, is now available at GNC and Sam's Club retail locations and online at their respective websites. The company said this expansion strengthens its retail footprint.

Why it matters — A NAGE watcher would care because broadening Tru Niagen distribution through major national retailers expands the product's market reach and retail presence.

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Business Wire · 12 Aug 2026neutral

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that senior management will present at the 17th Annual Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL. IDEAS Conferences are independent regional venues where top-tier companies present their investment merits to audiences of investors.

Why it matters — The presentation gives Niagen Bioscience management a platform to communicate the company's investment merits directly to an audience of investors at a regional conference.

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Business Wire · 6 Aug 2026positive

Niagen Bioscience, Inc. announced that Tru Niagen, described as the number one healthy-aging NAD+ supplement in the United States, is now available for purchase on Walmart.com. The company said the launch expands access to the product through one of the country's largest digital retail platforms.

Why it matters — This expands Tru Niagen's retail distribution and diversifies Niagen Bioscience's e-commerce marketplace presence, which is a relevant development for NAGE watchers tracking the company's commercial reach.

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the transcript of Niagen Bioscience, Inc.'s (NAGE) Q2 2026 earnings call. The item consists of the transcript's headline and source, with no details of the call's content provided.

Why it matters — A NAGE watcher would care because the earnings-call transcript serves as a reference record of management commentary and results from the company's Q2 2026 call.

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Zacks Investment Research · 4 Aug 2026neutral

Niagen Bioscience reported Q2 earnings of $0.01 per share, matching the Zacks Consensus Estimate. This compares to earnings of $0.04 per share in the same quarter a year earlier.

Why it matters — The result confirms NAGE met analyst expectations for the quarter, while highlighting a decline in year-over-year earnings per share.

FAQ

Frequently asked questions about NAGE stock

What is the NAGE stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Niagen Bioscience, Inc. have a median 12-month price target of $11, with estimates ranging from $8.5 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAGE stock a buy right now?

Of the 6 analysts covering Niagen Bioscience, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Niagen Bioscience, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAGE?

As at 22 Aug 2026, Niagen Bioscience, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will NAGE stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +227.1% from the last close, and Ticker Nerd's factor model ranks Niagen Bioscience, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAGE stock forecast for 2030?

No analyst covering Niagen Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $22 over the next 12 months.

How has NAGE stock performed over the past year?

Niagen Bioscience, Inc. returned -67.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Niagen Bioscience, Inc. do?

Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California.

What is the latest news on NAGE?

The most recent item we track (Business Wire, 20 Aug 2026): "Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club". Niagen Bioscience announced that Tru Niagen, its healthy-aging NAD-boosting supplement, is now available at GNC and Sam's Club retail locations and online at their respective websites. The company said this expansion strengthens its retail footprint.

Company

About Niagen Bioscience, Inc.

Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California. The company specializes in advancing NAD+ science to support cellular health and healthy aging through its proprietary Niagen platform, a patented NAD+-boosting ingredient known as nicotinamide riboside (NR). Niagen powers leading brands such as Tru Niagen, an oral supplement for consumer use, and Niagen Plus, which includes pharmaceutical-grade intravenous and injectable formulations available at clinics across the U.S. Niagen Bioscience Inc. operates ISO-accredited laboratories and maintains a reference standards business providing natural products, phytochemicals, and botanical reference materials for quality assurance in food, supplements, and research. It also runs the ChromaDex External Research Program, supplying high-quality NAD+ precursors to academic and government researchers worldwide. The company discovers, develops, and commercializes proprietary ingredient technologies targeting dietary supplements, food, beverages, skin care, and pharmaceutical markets, emphasizing science-backed innovation, clinical research, and regulatory compliance.

CEO Mr. Robert N. Fried · 117 employees · United States · https://www.niagenbioscience.com